CYP19A1 and breast cancer: The analysis revealed that compared to tamoxifen, 5 years of treatment with an aromatase inhibitor reduced the 10-year breast cancer mortality by 15%.352 In addition, several randomized trials have aimed to evaluate the efficacy of ovarian function suppression (OFS) and AIs in premenopausal women.